Summit Partners Public Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Summit Partners Public Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-84,515	Closed	-$5.35M	–	196
2023 Q2	$5.35M	Buy	84,515 +83,926	+14,249%	+$5.23M	0.2%	100
2023 Q1	$31.9K	Buy	+589	New	+$28.5K	﹤0.01%	105
2022 Q3	–	Sell	-138,331	Closed	-$7.9M	–	189
2022 Q2	$7.9M	Sell	138,331 -101,572	-42%	-$5.76M	0.36%	72
2022 Q1	$14.7M	Buy	+239,903	New	+$12.5M	0.52%	64

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Partners Public Asset Management's ITCI Position: Q3 2023 in Review

Summit Partners Public Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 84,515 shares — an estimated $5.35M sold.

Summit Partners Public Asset Management first reported a position in ITCI in Q1 2022 and held it in 4 quarters. The position peaked at $14.7M in Q1 2022. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

Summit Partners Public Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
Summit Partners Public Asset Management sold 84,515 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $5.35M.
Summit Partners Public Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 4 quarters.
Summit Partners Public Asset Management's Intra-Cellular Therapies Inc. position peaked at $14.7M in Q1 2022.
292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.